(19 March 2026, Hong Kong) HKSH Medical Group (HKSH) today announced the results of Asia’s first clinical study on early-stage prostate cancer patients receiving five-session of proton therapy.* The results show significant efficacy, with a marked decline in prostate-specific antigen (PSA) levels and only mild side effects. Proton therapy for prostate cancer generally requires about 30 treatment sessions over 8 to 9 weeks. Since the launch of proton therapy service in 2023, HKSH Cancer Centre has advanced the precision of treatment to achieve “hypofractionation”, drastically reducing the number of treatment session by 80%. For early-stage prostate cancer, there is an option of 5 sessions of proton therapy within 2 to 3 weeks to achieve disease control. The unique physical properties of proton beam can precisely target the tumour with minimal damage to nearby vital organs such as the bladder and bowel, thereby helping to enhance patients’ quality of life throughout their cancer journey.

Please click here for more details.